Fluoxetine in the Treatment of Bulimia Nervosa: A Multicenter, Placebo-Controlled, Double-blind Trial

Archives of General Psychiatry

Volumn 49, Issue 2, 1992, Pages 139-147

  Levine, Louise R ^b  

^a Fluoxetine Bulimia Nervosa Collaborative Study Group ^*

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; ASTHENIA; BULIMIA; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; FEMALE; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MYDRIASIS; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SWEATING; TREMOR; VASODILATATION;

ADULT; AMBULATORY CARE; BODY MASS INDEX; BULIMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOXETINE; HUMAN; PATIENT DROPOUTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SUPPORT, NON-U.S. GOV'T;

EID: 0026543528     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1992.01820020059008     Document Type: Article

References (49)

1. American Psychiatric Association, Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders—Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
2. Shotte DE, Stunkard AJ. Bulimia vs bulimic behaviors on a college campus. JAMA. 1987;258:1213-1215.
3. Thelen MH, McLaughlin L, Pruitt J, Smith M. Bulimia: prevalence and component factors in college women. J Psychosomat Res. 1987;31:73-78.
4. Pope HG Jr, Hudson JI, Yurgelun-Todd D. Anorexia nervosa and bulimia among 300 suburban women shoppers. Am J Psychiatry. 1984;141:292-294.
5. Pope HG Jr, Champoux RF, Hudson JI. Eating disorder and socioeconomic class: anorexia nervosa and bulimia in nine communities. J Nerv Ment Dis. 1987;175:620-623.
6. Mitchell JE, Seim HC, Colon E, Pomeroy C. Medical complications and medical management of bulimia. Ann Intern Med. 1987;107:71-77.
7. Herzog DB, Copeland PM. Eating disorders. N EnglJ Med. 1985;313:295-303.
8. Palmer EP, Guay AT. Reversible myopathy secondary to abuse of ipecac in patients with major eating disorders. N Engl J Med. 1985;314:1457-1459.
9. Pope HG Jr, Hudson JI, Nixon RA, Herridge PL. The epidemiology of ipecac abuse. N Engl J Med. 1986;314:245-246.
10. Pope HG Jr, Hudson JI, Jonas JM, Yurgelun-Todd D. Bulimia treated with imipramine: a placebo-controlled, doubleblind study. Am J Psychiatry. 1983;140:554-558.
11. Hughes PL, Wells LA, Cunningham CJ, Ilstrup DM. Treating bulimia with desipramine: a placebo-controlled double-blind study. Arch Gen Psychiatry. 1986;43:182-186.
12. Agras WS, Dorian BG, Kirkley BG, Arnow B, Bachman J. Imipramine in the treatment of bulimia: a double-blind controlled study. Int J Eating Disorders. 1987;6:29-38.
13. Kaplan AS, Garfinkel PE, Garner DM. Bulimia treated with carbamazepine and imipramine. Presented at the American Psychiatric Association Annual Meeting; May 13, 1987; chicago, Ill.
14. Barlow J, Blouin J, Blouin A, Perez E. Treatment of bulimia with desipramine: a double-blind crossover study. Can J Psychiatry. 1988;33:129-133.
15. Price WA, Babai MR. Antidepressant drug therapy for bulimia: current status revisited. J Clin Psychiatry. 1987;48:385.
16. Walsh BT, Gladis M, Roose SP, Stewart JW, Stetner F, Glassman AH. Phenelzine vs placebo in 50 patients with bulimia. Arch Gen Psychiatry. 1988;45:471-475.
17. Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE. A trial of isocarboxazid in the treatment of bulimia nervosa. J Clin Psychopharmacol. 1988;8:391-396.
18. Horne RL, Ferguson JM, Pope HG Jr, Hudson JI, Lineberry CG, Ascher J, Cato A. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry. 1988; 49:262-266.
19. Pope HG Jr, Keck PE Jr, McElroinSM, Hudson JI. A placebo-controlled study of trazodone in bulimia nervosa. J Clin Psychopharmacol. 1989;9:254-259.
20. Mitchell JE, Groat R. A placebo-controlled, double-blind trial of amitriptyline in bulimia. J Clin Psychopharmacol. 1984; 4:186-193.
21. Sabine EJ, Yonace A, Farrington AJ, Barratt KH, Wakeling A. Bulimia nervosa: a placebo-controlled double-blind therapeutic trial of mianserin. Br I Clin Pharmacol. 1983; 15(suppl):195S-202S.
22. Pope HG Jr, Hudson JI. Antidepressant drug therapy of bulimia: current status. J Clin Psychiatry. 1986;47:339-345.
23. Pope HG Jr, Hudson JI, Jonas JM. Antidepressant treatment of bulimia: preliminary experience and practical recommendations. J Clin Psychopharmacol. 1983;3:274-281.
24. Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry. 1985;46:32-37.
25. Feighner JP. Clinical efficacy of the new antidepressants. J Clin Pharmacol. 1981;1:235-265.
26. Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry. 1985;46:26-31.
27. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry. 1985;46:53-58.
28. Leibowitz SF, Brown O, Tretter JR, Kirschgessner A. Norepinephrine, clonidine, and tricyclic antidepressants selectively stimulate carbohydrate ingestion through noradrenergic system of the paraventricular nucleus. Pharmacol Biochem Behav. 1985;23:541-550.
29. Berken GH, Weinstein DO, Stern WC. Weight gain: a side effect of tricyclic antidepressants. J Affective Disord. 1984;7:133-138.
30. Fernstrom MD, Krowinski RL, Kupfer DJ. Chronic imipramine treatment and weight gain. Psychiatry Res. 1986; 17:269-273.
31. Ferguson JM, Feighner JP. Fluoxetine-induced weight loss in overweight nondepressed humans. Int J Obesity. 1987;11(suppl):179S-184S.
32. Levine LR, Rosenblatt S, Bosomworth JC. Use of serotonin reuptake inhibitor, fluoxetine, in the treatment of obesity. IntJ Obesity. 1987;11(suppl):185S-190S.
33. Pope HG Jr, Hudson JI. New Hope for Binge Eaters: Advances in the Understanding and Treatment of Bulimia. New York, NY: Harper & Row Publishers Inc; 1984.
34. Freeman CPL, Hampson M. Fluoxetine as a treatment for bulimia nervosa. Int J Obesity. 1987;11(suppl):171S-177S.
35. Freeman CP, Munro JK. Drug and group treatments for bulimia/bulimia nervosa. J Pychosom Res. 1988;32:647-660.
36. Levine LR, Enas GG, Thompson WL, Byyny RL, Dauer AD, Kirby RW, Kreindler TG, Levy B, Lucas CP, Mcllwain HH, Nelson EB. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. Int J Obesity. 1989;13:635-645.
37. Metropolitan Life Insurance Company. Height and weight tables. Metropolitan Life Foundation Statistical Bulletin. 1983;64:62.
38. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-65.
39. Garner DM, Olmstead MP, Polivy J. Development and validation of a multidimensional eating disorder inventory for anorexia nervosa and bulimia. Int J Eating Disorders. 1983;2:15-34.
40. Garner DM, Olmstead MP, Bohr Y, Garfinkel PE. The eating attitude test: psychometric features and clinical correlates. Psychol Med. 1982;12:871-878.
41. Wurtman JJ, Wurtman RJ. Suppression of carbohydrate intake from snacks and meals by d-fenfluramine and tryptophan. In: Garrattini S, ed. Anorectic Agents: Mechanisms of Action and Tolerance. New York, NY: Raven Press; 1981:169-181.
42. US Food and Drug Administration. COSTART Coding Symbols for Thesaurus of Adverse Reaction Terms. 2nd ed. Rockville, Md: Food and Drug Administration; 1985.
43. SAS/STAT User's Guide, Version 5 Ed. Cary, NC: SAS Institute Inc; 1985:2.
44. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273-3277.
45. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry. 1985;46:14-19.
46. Wernicke JF, Dunlop SR, Dornseif BG, Zerbe RL. Fixed dose fluoxetine therapy for depression. Psychopharmacol Bull. 1987;23:164-168.
47. Wurtman JJ, Wurtman RJ. Drugs that enhance central serotonergic transmission diminish elective carbohydrate consumption by rats. Life Sci. 1980;24:825-826.
48. Kaye WH, Gwirtsman HE, Brewerton TD, George DT, Wurtman RJ. Bingeing behavior and plasma amino acids: a possible involvement of brain serotonin in bulimia nervosa. Psychiatry Res. 1988;23:31-43.
49. Fernstrom JD, Wurtman RJ. Brain serotonin content: increase following ingestion of carbohydrate diet. Science. 1971;174:1023-1025.